Promac signature application

• US 20070202515A1
• Filed: 10/12/2006
• Published: 08/30/2007
• Est. Priority Date: 10/12/2005
• Status: Abandoned Application

• Current Assignee: Pathologica, Llc
• Original Assignee: Pathologica, Llc
• Inventors: Hadlock, Kenneth, Lancero, Hope, Yu, Stephanie, Do, Hien
• Application Number:
  US11/549,019
• Publication Number:
  US 20070202515A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: B82Y 15/00 Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• CPC Class Codes: B82Y 30/00 Nanotechnology for materials or surface science, e.g. nanocomposites
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention is directed to ProMac signature genes and methods and kits for using the ProMac signature genes for diagnostic, prognostic, or monitoring ProMac associated diseases.

Claims

1. A method for diagnosing a neurodegenerative disorder in a subject comprising detecting the expression of a panel of ProMac signature genes in a biological sample of the subject, wherein a higher than normal level of expression of the panel of ProMac signature genes is indicative of a neurodegenerative disorder in the subject.

2. The method of claim 1, wherein the expression of the panel of ProMac signature genes includes transcription, translation, or activation of the panel of ProMac signature genes.

3. The method of claim 1, wherein the panel of ProMac signature genes comprise at least two ProMac signature genes.

4. The method of claim 1, wherein the panel of ProMac signature genes comprise at least four ProMac signature genes.

5. The method of claim 1, wherein the panel of ProMac signature genes comprise at least five ProMac signature genes.

6. The method of claim 1, wherein the panel of ProMac signature genes comprise at least eight ProMac signature genes.

7. The method of claim 1, wherein the panel of ProMac signature genes are selected from the group consisting of the genes listed in Table 28.

8. The method of claim 1, wherein the panel of ProMac signature genes are selected from the group consisting of genes listed in Table 21.

9. The method of claim 1, wherein the panel of ProMac signature genes are selected from the group consisting of genes listed in Table 29.

10. The method of claim 1, wherein the panel of ProMac signature genes are selected from the group consisting of CLEC4E, G1P3, GPR109B, IFIT2, IL1RN, MX2, NBS1, and ORM1.

11. The method of claim 1, wherein the panel of ProMac signature genes are selected from the group consisting of G1P3, GPR43, IFIT2, ORM1, and TNFSF10.

12. The method of claim 1, further comprising detecting the expression of a panel of ProMac secondary signature genes, wherein a higher than normal level of expression of the panel of ProMac signature genes and ProMac secondary signature genes is indicative of a neurodegenerative disorder in the subject.

13. The method of claim 12, wherein the panel of ProMac secondary signature genes are selected from the group consisting of genes listed in Table 30.

14. The method of claim 12, wherein the panel of ProMac secondary signature genes comprise at least two ProMac secondary signature genes.

15. The method of claim 12, wherein the panel of ProMac secondary signature genes are selected from the group consisting of ALAS2, BTNL8, CKLFSF2, CR1L, CSF3R, FCAR, FCGR3B, GMPB, IF127, IL8RA, IL8RB, JAG1, KCNJ15, P2RY13, PBEF1, PLAU, PLXNC1, SLENBP1, SLC25A37, and TNFRSF10C.

16. The method of claim 1, wherein the neurodegenerative disorder is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Charcot-Marie Tooth syndrome, Alzheimer'"'"'s disease (AD), HIV-associated dementia (HAD), HIV associated neurological disorders, peripheral sensory neuropathy, diabetic neuropathy, autism, Parkinson'"'"'s disease, schizophrenia, and multiple sclerosis.

17. A kit comprising one or more probes useful for detecting the expression of a panel of ProMac signature genes in a sample from a subject.

18. The kit of claim 17, wherein the probes are oligonucleotides.

19. The kit of claim 17, wherein the probes are antibodies.

20. The kit of claim 17, wherein the panel of ProMac signature genes comprise at least two ProMac signature genes.

21. The kit of claim 17, wherein the panel of ProMac signature genes comprise at least four ProMac signature genes.

22. The kit of claim 17, wherein the panel of ProMac signature genes comprise at least five ProMac signature genes.

23. The kit of claim 17, wherein the panel of ProMac signature genes comprise at least eight ProMac signature genes.

24. The kit of claim 17, wherein the panel of ProMac signature genes are selected from the group consisting of the genes listed in Table 28.

25. The kit of claim 17, wherein the panel of ProMac signature genes are selected from the group consisting of genes listed in Table 21.

26. The kit of claim 17, wherein the panel of ProMac signature genes are selected from the group consisting of genes listed in Table 29.

27. The kit of claim 17, wherein the panel of ProMac signature genes are selected from the group consisting of CLEC4E, G1P3, GPR109B, IFIT2, IL1RN, MX2, NBS1, and ORM1.

28. The kit of claim 17, wherein the panel of ProMac signature genes are selected from the group consisting of G1P3, GPR43, IFIT2, ORM1, and TNFSF10.

29. A method for distinguishing a first neurodegenerative disorder from a second neurodegenerative disorder comprising

evaluating the expression of a panel of ProMac secondary signature genesassociated with the first and the second neurodegenerative disorder in a biological sample from the subject, and

correlating the expression of the panel of ProMac secondary signature genes with the determination of the first neurodegenerative disorder or the second neurodegenerative disorder,

wherein the first neurodegenerative disorder is cerebral neuron degeneration and the second neurodegenerative disorder is motor neuron degeneration.

30. The method of claim 29, wherein the first neurodegenerative disorder is Alzheimer'"'"'s disease (AD) and the second neurodegenerative disorder is amyotrophic lateral sclerosis (ALS).

31. The method of claim 29, wherein a higher than normal level of expression of the panel of ProMac secondary signature genes is indicative of the first neurodegenerative disorder.

32. The method of claim 29, wherein the panel of ProMac secondary signature genes are selected from the group consisting of 8pGAG, CSF3R, GOLGIN-67, IL6, JAG1, MSP, RAD51L3, and TPD52.

33. The method of claim 29 further comprising evaluating the expression of a panel of ProMac signature genes.

34. The method of claim 33, wherein the panel of ProMac signature genes are selected from the group consisting of CHI3L1, CXCL1L, GPR43, ILRN, ORM1, and PI3.

35. A method for monitoring the treatment of a neurodegenerative disease in a subject comprising monitoring the expression of a panel of ProMac signature genes in a biological sample from the subject, wherein the level of expression of the panel of ProMac signature genes positively correlates with the progress of the neurodegenerative disease in the subject.

36. A method for monitoring the treatment of a ProMac associated disease in a subject comprising monitoring the expression of a panel of ProMac signature genes in a biological sample from the subject, wherein the level of expression of the panel of ProMac signature genes positively correlates with the progress of the ProMac associated disease in the subject.

37. A method for monitoring the level of disease associated macrophages in a subject comprising monitoring the expression of a panel of ProMac signature genes in a biological sample from the subject, wherein the level of expression of the panel of ProMac signature genes positively correlates with the level of disease associated macrophages in the subject.

38. A method for evaluating an agent comprising contacting the agent with a macrophage and evaluating the expression of a panel of ProMac signature genes in the presence and absence of the agent, wherein a change caused by the agent is indicative of the agent as a modulator of ProMac.

39. A method for providing a prognosis of a ProMac associated disease in a subject comprising detecting the expression of a panel of ProMac signature genes in a biological sample from the subject, wherein the expression of the panel of ProMac signature genes is negatively associated with a positive outcome of the ProMac associated disease.

40. The method of claim 39, wherein the ProMac associated disease is a neurodegenerative disorder.

41. The method of claim 39 further comprising detecting the expression of a panel of ProMac secondary signature genes.

42. The method of claim 41, wherein the secondary signature genes are selected from the group consisting of CD14, CLEC7A, FCAR, FCGR1a, GOLGIN-67, GPR86, HIP1, RAD51L3, and 8PGAG.

43. The method of claim 39, wherein the panel of ProMac signature genes are selected from the group consisting of CHI3L1, CLEC4E, G1P3, GPR43, GPR109B, IFIT2, MX2, NBS1, OAS3, ORM1, SLPI, and TNFSF10.

44. A method for providing a prognosis of a ProMac associated disease in a subject comprising detecting the expression of a panel of ProMac secondary signature genes in a biological sample from the subject, wherein the expression of the panel of ProMac secondary signature genes is negatively associated with a positive outcome of the ProMac associated disease.

45. The method of claim 44, wherein the ProMac secondary signature genes are selected from the group consisting of CD14, CLEC7A, FCAR, FCGR1a, GOLGIN-67, GPR86, HIP1, RAD51L3, and 8PGAG.

46. The method of claim 44, wherein the ProMac associated disease is amyotrophic lateral sclerosis (ALS).